[Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation]

Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L
Record ID 32010001765
Hungarian, English
Authors' recomendations: Abatacept is an effective treatment for RA compared to placebo in terms of improving symptoms and health related quality of life. The cost utility of the abatacept is between 3.6-8.7 million HUF/QALY compared to methotrexate. Abatacept therapy is dominant strategy compared to cycled TNF-alfa inhibitors.
Details
Project Status: Completed
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Hungary
MeSH Terms
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Cost-Benefit Analysis
  • Immunoconjugates
Contact
Organisation Name: Unit of Health Economics and Technology Assessment in Health Care
Contact Address: Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name: laszlo.gulacsi@uni-corvinus.hu
Contact Email: laszlo.gulacsi@uni-corvinus.hu
Copyright: Unit of Health Economics and Technology Assessment in Health Care (HunHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.